{"id":12779,"date":"2026-05-29T00:14:00","date_gmt":"2026-05-28T22:14:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=428dfd20aaa67316d5228c58a3af414a"},"modified":"2026-05-29T00:14:00","modified_gmt":"2026-05-28T22:14:00","slug":"law-offices-of-howard-g-smith-encourages-zoetis-inc-zts-shareholders-to-inquire-about-securities-fraud-class-action","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=12779","title":{"rendered":"Law Offices of Howard G. Smith Encourages Zoetis Inc. (ZTS) Shareholders To Inquire About Securities Fraud Class Action"},"content":{"rendered":"

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Zoetis Inc. (\u201cZoetis\u201d or the \u201cCompany\u201d) (NYSE: ZTS<\/a>) securities between January 14, 2025 and May 6, 2026<\/b>, inclusive (the \u201cClass Period\u201d). Zoetis investors have until July 27, 2026 <\/b>to file a lead plaintiff motion.<\/p>

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ZOETIS INC. (ZTS), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.<\/b><\/p>

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@howardsmithlaw.com<\/a>, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com<\/a>.<\/p>

What Happened?<\/b><\/p>

On August 5, 2025, Zoetis released its second quarter 2025 financial results, reporting weakened demand trends within its Companion Animal portfolio.<\/p>

On this news, Zoetis\u2019 stock price fell $5.69, or 3.8%, to close at $146.12 per share on August 5, 2025, thereby injuring investors.<\/p>

Then, on November 4, 2025, Zoetis released its third quarter 2025 financial results, revealing slowed growth across its key Companion Animal franchises and disclosing continued weakness in sales of its canine pain treatment, Librela, and increased competitive pressure in dermatology and parasiticides. The Company also lowered its full year sales outlook.<\/p>

On this news, Zoetis\u2019 stock price fell $19.89, or 13.8%, to close at $124.46 per share on November 4, 2025.<\/p>

Then, on May 7, 2026, Zoetis released its first quarter 2026 financial results, reporting slowing overall revenue growth, declining Companion Animal sales performance, and worsening results across its key dermatology and parasiticides franchises, stating that \u201ccompetition intensified across key pet care categories, including dermatology and parasiticides,\u201d that \u201cpet owners demonstrated increased price sensitivity,\u201d and that \u201cthese new entrants have not yet translated into overall market expansion.\u201d<\/p>

The Company also explained that \u201cprice has played a larger role in the decision process,\u201d that \u201c[s]hare loss is being amplified by a derm market with declining patient volume in the clinic,\u201d and that contraction in the parasiticides market was negatively impacting prescription volumes and compliance. In addition, the Company admitted that it was operating in \u201ca more price sensitive and competitive environment\u201d and further reduced its 2026 growth outlook based on continuing competitive and operating pressures.<\/p>

On this news, Zoetis\u2019 stock price fell $23.91, or 21.5%, to close at $87.31 per share on May 7, 2026, thereby injuring investors further.<\/p>

What Is The Lawsuit About?<\/b><\/p>

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and\/or misleading statements, as well as failed to disclose material adverse facts about the Company\u2019s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) veterinarian prescription growth and adoption of Zoetis\u2019 Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs; (2) Zoetis\u2019 Simparica Trio was losing significant market share to a lower priced competing canine parasiticide with broader indicated use in a slowing overall market; and (3) Zoetis\u2019 dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment; and (4) as a result, Defendants\u2019 positive statements about the Company\u2019s business, operations, and prospects were materially misleading and\/or lacked a reasonable basis at all relevant times.<\/p>

Contact Us To Participate or Learn More:<\/b><\/p>

If you purchased Zoetis securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:<\/p>

Law Offices of Howard G. Smith,3070 Bristol Pike, Suite 112,Bensalem, Pennsylvania 19020,Telephone: (215) 638-4847Email: howardsmith@howardsmithlaw.com<\/a>,Visit our website at: www.howardsmithlaw.com<\/a>.<\/p>

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.<\/p> Contacts<\/b>

Law Offices of Howard G. SmithHoward G. Smith, Esquire215-638-4847howardsmith@howardsmithlaw.com<\/a>www.howardsmithlaw.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

BENSALEM, Pa.–(BUSINESS WIRE)–Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Zoetis Inc. (\u201cZoetis\u201d or the \u201cCompany\u201d) (NYSE: ZTS) securities between January 14, 2025 and May 6, …<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-12779","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/12779","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=12779"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/12779\/revisions"}],"predecessor-version":[{"id":12780,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/12779\/revisions\/12780"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12779"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=12779"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=12779"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}